|
| |
Amgen IncAmgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives.Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
| Contact Details: |
| One Amgen Center Drive |
| Thousand Oaks |
| California |
| 91320-1799 |
| United States of America |
| Tel: | 1 805-447-1000 |
| Fax: | 1 805-447-1010 |
| Email: | investor.relations@amgen.com |
| WWW: | www.tularik.com/
|
|
Loading...
|
Recent Publications by Amgen Inc: |  |
Tetrahydroquinoline derivatives as CRTH2 antagonists.
A series of tetrahydroquinoline-derived inhibitors of the CRTH2 receptor... | 10th November, 2009
| Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.
| Bioorg Med Chem Lett. 2009 Dec 15;19(24):6840-4. Epub 2009 Oct 25.
DOI Direct Link |
Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.
Erythropoietin (Epo) binds and activates the Epo receptor (EpoR) on the... | 6th November, 2009
| Amgen Inc, One Amgen Center, Thousand Oaks, CA 91320, United States.
| J Immunol Methods. 2009 Nov 1.
DOI Direct Link |
Relationship between Passive Permeability, Efflux, and Predictability of Clearance from in vitro Metabolic Intrinsic Clearance.
In vitro intrinsic metabolic clearance (CL(int)) is used routinely for... | 31st October, 2009
| 1 Amgen Inc;
| Drug Metab Dispos. 2009 Oct 29.
DOI Direct Link |
Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors.
Cyclin-dependent kinase 5 (CDK5) is a serine-threonine protein kinase that... | 30th October, 2009
| Chemistry Research and Discovery, Amgen Inc, One Amgen Center Drive,
| Bioorg Med Chem Lett. 2009 Dec 1;19(23):6591-4. Epub 2009 Oct 13.
DOI Direct Link |
Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction.
Tumor protein 53 (p53) is a critical regulator of cell cycle and apoptosis... | 28th October, 2009
| Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive,
| J Med Chem. 2009 Nov 26;52(22):7044-7053.
DOI Direct Link |
→View more Amgen Inc research publications. |
Press Releases on Amgen Inc:
|
 |
| American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure Patients |
17th November, 2009 |
American Heart Association |
Study highlights:
-- Iron treatment with intravenous (I.V.) ferric carboxymaltose significantly improved symptoms, functional capacity and quality of life for Class II and III chronic heart failure
|
| Trubion Pharmaceuticals, Inc. Announces Transition in Company Leadership |
16th November, 2009 |
Trubion Pharmaceuticals, Inc. |
SEATTLE, Nov. 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that Peter Thompson, M.D., FACP, President, Chief Executive Officer, Chairman of the Board of
|
| Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs |
28th October, 2009 |
Santaris Pharma A/S |
HOERSHOLM, Denmark and SAN DIEGO, California, October 28 /PRNewswire/ --
- Industry Expert Mark Wedel, MD, FACP Joins as Vice President and Chief
Medical Officer Responsible for Global
|
| Organovo Appoints Robert Baltera to Board |
27th October, 2009 |
Organovo, Inc. |
SAN DIEGO, Oct. 27 /PRNewswire/ -- Organovo, Inc., a regenerative medicine company focused on bioprinting technology, announced today the appointment of Robert Baltera, M.S., M.B.A, to its board of
|
| Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49 |
21st October, 2009 |
Amgen |
THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 181 individuals from Amgen Inc using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 650 times since April 2007, the link to the organisation's website has been followed 69 times Recent Search Terms used to find this page: Amgen united states contact number 1 | organovo inc. tel | amgen 2009 biotechnology strategy | Amgen Inc. logo | Jay Hagan Amgen | amgen tweak | bioportfolio amgen | amgen tweak | Jay Hagan OREXIGEN THERAPEUTICS INC | Jay Hagan email Orexigen | . Search for more companies in Thousand Oaks Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Amgen Inc |
